SAVA, a startup based in London, has recently raised $8 million (£6.3 million) in Seed funding to develop preventative, personalised, precision health monitoring at scale. Founded by Renato Circi and Rafael Michali, SAVA is known for its groundbreaking microsensor technology capable of detecting biomarkers just below the skin's surface. The company's initial focus is on disrupting the Continuous Glucose Monitoring market by providing a pain-free, low-cost, and accurate solution for patients with diabetes.
With the recent funding, SAVA plans to expand its team, design a next-generation product line with high-throughput manufacturing capability, and demonstrate the platform's clinical performance.
The startup has gained approval from the UK's Medicines and Healthcare Products Regulatory Agency to proceed with clinical trials on patients with diabetes, marking a significant milestone in validating its technology. SAVA's ultimate goal is to offer pain-free, real-time insights to users at an affordable price, with upcoming clinical studies set to involve world-leading investigators from prestigious universities.
While SAVA's current focus lies in glucose monitoring for individuals with diabetes, the startup's modular design allows for the potential simultaneous monitoring of multiple molecules in the future. Multi-analyte sensing opens doors to monitoring a wide range of conditions and applications beyond diabetes care. With the support of leading VC firms, angel investors, and government funding, SAVA aims to revolutionize healthcare by providing a new paradigm focusing on preventative, personalised, and painless health monitoring. Co-founder Renato Circi expressed the team's commitment to making world-leading monitoring technology accessible to all, while co-founder Rafael Michali highlighted SAVA's mission to empower individuals to take control of their health through real-time insights.
Click here for a full list of 6,528+ startup investors in the UK